BILL ANALYSIS

HR1931

BULLISH

Access to Pediatric Technologies Act of 2025

HR1931 (Access to Pediatric Technologies Act of 2025) carries an AI-assessed market impact score of 3/10 with a bullish outlook for investors. This legislation directly affects Abbott Laboratories ($ABT), Merck ($MRK) and Pfizer ($PFE). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

3/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR1931 is an early-stage bill with zero legislative progress in 13+ months; passage in the 119th Congress is unlikely

The bill creates a regulatory mechanism for Medicare reimbursement of pediatric technologies - it authorizes no direct spending

Impact on public med-tech and pharma companies (JNJ, ABT, MRK, PFE) is directionally positive but economically negligible given these companies' massive revenue bases

No real market price movement can be attributed to this bill - stock trends are driven by broader healthcare sector weakness

How HR1931 Affects the Market

No immediate market implications. The bill is stuck in committee with no hearings scheduled. The 30-day price action for JNJ (-6.24%), ABT (-10.36%), MRK (-6.05%), and PFE (-5.44%) reflects broader sector selling, not legislative catalysts. Investors should treat this as a long-term policy signal that pediatric device/drug reimbursement is on Congress's radar, not a near-term trading catalyst. A committee hearing or markup would be the first actionable signal of momentum.

Bill Details

Metric	Value
Bill Number	HR1931
Impact Score	3/10Certainty: Committee hearing · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 3/10 · Market Penetration: 3 companies directly affected
Market Sentiment	bullish
Event Date	March 6, 2025
Affected Sectors	Healthcare
Affected Stocks	Abbott Laboratories ($ABT), Merck ($MRK), Pfizer ($PFE)
Source	View on Congress.gov →

Summary

HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.

Full AI Market Analysis

1) On March 6, 2025, Rep. John Joyce (R-PA) introduced HR1931, the Access to Pediatric Technologies Act of 2025. The bill was referred to both the Energy and Commerce Committee and Ways and Means Committee. As of today (April 30, 2026), the bill remains in early committee stages with no hearings, markups, or floor votes. A companion bill S249 was introduced in the Senate and referred to Finance Committee. Legislative velocity is low - zero actions in 13+ months since referral. 2) The bill does not authorize or appropriate any funding. It creates a regulatory mechanism: upon request from a manufacturer, CMS must establish national relative value units under the Medicare physician fee schedule for a 'qualifying pediatric technology' - defined as a Medicare-covered, FDA-approved device that is predominantly used for pediatric patients. The payment methodology is developed using contractor pricing, claims data, and other information. This is permanent statutory authority, not a one-time funding allocation. 3) Structural winners are companies with existing or pipeline pediatric medical devices and drugs that are Medicare-covered. JNJ (pediatric surgical, orthopedic, and pharmaceutical products), ABT (pediatric nutrition, diagnostics, devices), MRK (pediatric vaccines, pediatric oncology), and PFE (pediatric vaccines, rare disease) would benefit from reduced reimbursement uncertainty. However, the impact is marginal for these diversified giants - pediatric-specific Medicare revenue is a rounding error on their total revenue. Pure-play pediatric med-tech companies (mostly private or very small) would be the most proportionally affected, but no public pure-play pediatric device companies exist on US exchanges. 4) Real market data shows all four tickers in a 30-day downtrend: JNJ -6.24% (current $227.35), ABT -10.36% (current $91.33 - near 52-week low of $90.72), MRK -6.05% (current $110.95), PFE -5.44% (current $26.26). These moves are driven by broader market and sector factors, not by this bill's prospects. The bill's early-stage status means zero market price impact to date. 5) Timeline: The bill requires committee hearings and a vote in both Energy & Commerce and Ways and Means before a House floor vote. Companion S249 needs Senate Finance Committee action. With no action in 13 months and the 119th Congress halfway through its two-year session (2025-2027), the probability of passage in this Congress is low. If reintroduced in the 120th Congress (2027-2029), the timeline resets.